Post-Conference Report
This post-conference report offers a complete guide to all the RNA topics and provides analysis and a summary of abstracts. Overall, the 20 abstracts presented data for 21 drugs and 13 trials, with the most investigated drug being mRNA-4157, which featured in 2 abstracts, along with its associated phase 2 trial. Find all about them by downloading the report.
Related content
The 2023 H1 RNA Landscape Review
Realizing the Full Potential within the RNA and Gene Therapy Landscapes: 2023 So Far
RNA: ASCO Post-Conference Report 2023
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our Team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
